Sentences with phrase «for treating lung cancer»

A new drug delivery system for treating lung cancer allow chemotherapeutic drugs to be inhaled, thereby delivering the drug where it is needed while reducing the harmful effects to other organs.

Not exact matches

Since then, the companies have been scrambling to rack up indications for the rival drugs, which are both approved for treating melanoma and lung cancer.

They'll also jointly market Pfizer's drug Xalkori, which is approved in more than 75 countries for treating non-small cell lung cancer in patients with a certain genetic mutation.

The proportion of patients treated within 62 days of an urgent GP referral for various cancer types is as follows: Lung cancers — 83.3 % treated within 62 days of an urgent GP referral for suspected cancer.

«Our study suggests that epigenetic changes to cells treated with cigarette smoke sensitize airway cells to genetic mutations known to cause lung cancers,» says Stephen Baylin, M.D., the Virginia and D.K. Ludwig Professor for Cancer Research and professor of oncology at the Johns Hopkins Kimmel Cancer Center.

The median age was 66 and the majority of patients (88 percent) were treated for primary lung cancer.

«One of the toughest challenges of lung cancer is what to do for patients when the cancer comes back in an area that's been treated previously with radiation treatment,» said James J. Urbanic, M.D., lead author of the studies and a radiation oncologist at Wake Forest Baptist.

If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»

In addition, the study showed that the 5 - year survival rate for selected older patients with advanced lung cancer who were treated with surgical therapy was 29.9 % for Stage III and 26.7 % for Stage IV.

Both drugs are approved for treating metastatic melanoma, and Opdivo is also approved for squamous lung cancer.

Until now, EGFR inhibitors have only been effective at treating the 10 to 15 percent of non-small cell lung cancers that have a variant of EGFR, but the two - drug combo could potentially work for all non-small cell lung cancers, explained Dr. John Minna, Director of the Hamon Center for Therapeutic Oncology Research and Professor of Internal Medicine and Pharmacology.

The FDA has approved several ALK inhibitors for treating non-small cell lung cancer.

To demonstrate the potential for treating lung disease, the researchers used the nanoparticles to block two genes that have been implicated in lung cancer — VEGF receptor 1 and Dll4, which promote the growth of blood vessels that feed tumors.

For example, the drug crizotinib approved to treat ALK - positive lung cancer, showed a PFS of 10.9 months.

This shows promise for breast cancer patients as diagnosing and treating the breast cancer at early stages means there is a greater chance of preventing cancer cells spreading to other tissues, such as the lungs, brain and bone.

The study, called «Molecular Determinants of Drug - Specific Sensitivity for Epidermal Growth Factor Receptor (EGFR) Exon 19 and 20 Mutants in Non-Small Cell Lung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patieLung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patCancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patielung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patcancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patients.

For example, Zykadia, a drug for metastatic lung cancer, received a «breakthrough therapy» designation that allows expedited approval based on preliminary evidence for certain drugs that treat serious conditioFor example, Zykadia, a drug for metastatic lung cancer, received a «breakthrough therapy» designation that allows expedited approval based on preliminary evidence for certain drugs that treat serious conditiofor metastatic lung cancer, received a «breakthrough therapy» designation that allows expedited approval based on preliminary evidence for certain drugs that treat serious conditiofor certain drugs that treat serious conditions.

Previous work at CU Cancer Center shows these drugs are especially useful against lung cancers that over-express both EGFR and HER2, implying that in addition to targeting HER2 - positive lung cancers with drugs approved to treat HER2 - positive breast cancers, there may be a role for HER2 inhibitors in HER2 cancers, perhaps both breast and lung.

«In this study, outcomes for HER2 - positive lung cancer patients treated with conventional therapies were similar to outcomes for HER2 - negative patients treated in the same way.

Researchers and physicians have shown success treating EGFR lung cancer, for example with EGFR inhibitors gefitinib and erlotinib.

With the advancement of surgical and radiation therapy strategies for stage 1 non-small-cell lung cancer (NSCLC), more patients are being treated, resulting in higher survival rates, according to a study published online today in The Annals of Thoracic Surgery.

The European Lung Cancer Conference (ELCC) is the reference event in Europe for professionals treating lung cancLung Cancer Conference (ELCC) is the reference event in Europe for professionals treating lung canclung cancers.

LA JOLLA, CA — Drugs targeting an enzyme involved in inflammation might offer a new avenue for treating certain lung cancers, according to a new study by scientists at the Salk Institute for Biological Studies.

Cancer Institute research highlights include innovative studies to develop individualized approaches for treatment and prevention of lung cancer; collaboration between medical and materials science researchers to develop treatments for various types of leukemia using nanotechnology to target only cancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor develoCancer Institute research highlights include innovative studies to develop individualized approaches for treatment and prevention of lung cancer; collaboration between medical and materials science researchers to develop treatments for various types of leukemia using nanotechnology to target only cancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor develocancer; collaboration between medical and materials science researchers to develop treatments for various types of leukemia using nanotechnology to target only cancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor develocancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor development.

(PHILADELPHIA)-- The most common type of lung cancer, non-small cell lung cancer (NSCLC), continues to be difficult to treat, with five year survival rates of about 36 percent for stage 3A tumors.

But I very well likely will be treating them in five years — and that's a new story for lung cancer.»

Dr Lesley Walker, Cancer Research UK's director of cancer information, said: «We've made progress in recent years to discover new ways to tackle lung cancer and this important trial brings further opportunities for this hard to treat diCancer Research UK's director of cancer information, said: «We've made progress in recent years to discover new ways to tackle lung cancer and this important trial brings further opportunities for this hard to treat dicancer information, said: «We've made progress in recent years to discover new ways to tackle lung cancer and this important trial brings further opportunities for this hard to treat dicancer and this important trial brings further opportunities for this hard to treat disease.

Prognosis of lung cancer is poor; around 7 % of patients survive for five years, and most patients are treated palliatively from diagnosis.

«This is particularly important for hard to treat cancers like pancreatic, oesophageal, lung and brain tumours.

The first UK license for CRISPR / Cas9 use in editing genes in human embryos was granted in 2016, xvii and CRISPR - edited cells to treat lung cancer were administered in the world's first human trials for the technique by a Chinese group in late 2016.

With survival rates that haven't changed significantly for decades, cancers of the brain, lung, oesophagus and pancreas are notoriously difficult to treat and remain diseases of substantial unmet need.

Merck's cancer drug Keytruda got the nod of U.S. regulators as a first - line drug for treating metastatic non-small cell lung cancer.

For example, breast cancer is the most common cancer diagnosis, but lung cancer — often diagnosed at a late stage — is more difficult to treat and deadly.

He is alive, but has been treated for lung cancer in his past.

Jeff Gold, the author for Treat Cancer Naturally in Dogs can not hide his elation as he tells of how two of his dogs survived lung and bladder cancer respectCancer Naturally in Dogs can not hide his elation as he tells of how two of his dogs survived lung and bladder cancer respectcancer respectively.